Introduction to ‘Spotlight on myeloproliferative neoplasms’

Introduction to a review series on myeloproliferative neoplasms.

According toPubMed, the adjective“myeloproliferative”wasused for the first time in the title of a scientific paper by William Dameshek in 1951, when he published an editorial in Blood entitled, “Some speculations on the myeloproliferative syndromes.” In this article, featured in the recent Blood Flashback series, Dameshek introduced the concept of myeloproliferative disorders as conditions char...

Effects of Mutational Combinations on Philadelphia-Negative Myeloproliferative Neoplasms

Blood Spotlight From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms

Our knowledge of the genetic basis of these disorders began in 2005, when a unique base substitution in JAK2, the gene encoding Janus kinase 2,was found inpatientswith polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The background of our investigations was the previous finding that copy-neutral loss of heterozygosity of chromosome 9p (9pLOH) is the most common chromosom...

Myeloproliferative neoplasms and thrombosis.

Major causes of morbidity and mortality in myeloproliferative neoplasms are represented by arterial and venous complications, progression to myelofibrosis, and transformation to acute leukemia. The pathogenesis of thrombosis results from a complex interplay of clinical and disease-related factors. Abnormalities of blood cells arising from the clonal proliferation of hematopoietic stem cells inv...

Myelodysplastic/myeloproliferative neoplasms.

According to the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues, myelodysplastic/myeloproliferative neoplasms are clonal myeloid neoplasms that have some clinical, laboratory, or morphologic findings that support a diagnosis of myelodysplastic syndrome, and other findings that are more consistent with myeloproliferative neoplasms. These disorders ...